These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 28388541)

  • 41. Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.
    Müller V; Clemens M; Jassem J; Al-Sakaff N; Auclair P; Nüesch E; Holloway D; Shing M; Bang YJ
    BMC Cancer; 2018 Mar; 18(1):295. PubMed ID: 29544445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
    Li C; Wang B; Chen SC; Wada R; Lu D; Wang X; Polhamus D; French J; Vadhavkar S; Strasak A; Smitt M; Joshi A; Samant M; Quartino A; Jin J; Girish S
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1079-1090. PubMed ID: 29022084
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Analysis of Chemotherapy with Trastuzumab in Advanced Gastric Cancer].
    Kawada J; Nakatsuka R; Motoori M; Miyazaki S; Danno K; Kubota M; Matsuda C; Nishikawa K; Fujitani K; Iwase K; Tsujinaka T; Tanaka Y
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2091-3. PubMed ID: 26805274
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.
    Pietrantonio F; Caporale M; Morano F; Scartozzi M; Gloghini A; De Vita F; Giommoni E; Fornaro L; Aprile G; Melisi D; Berenato R; Mennitto A; Volpi CC; Laterza MM; Pusceddu V; Antonuzzo L; Vasile E; Ongaro E; Simionato F; de Braud F; Torri V; Di Bartolomeo M
    Int J Cancer; 2016 Dec; 139(12):2859-2864. PubMed ID: 27578417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.
    Jankowski C; Guiu S; Cortet M; Charon-Barra C; Desmoulins I; Lorgis V; Arnould L; Fumoleau P; Coudert B; Rouzier R; Coutant C; Reyal F
    Breast Cancer Res Treat; 2017 Jan; 161(1):73-81. PubMed ID: 27807808
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102).
    Nishikawa K; Takahashi T; Takaishi H; Miki A; Noshiro H; Yoshikawa T; Nishida Y; Iwasa S; Miwa H; Masuishi T; Boku N; Yamada Y; Kodera Y; Yoshida K; Morita S; Sakamoto J; Saji S; Kitagawa Y
    Int J Cancer; 2017 Jan; 140(1):188-196. PubMed ID: 27521503
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab.
    Bang K; Cheon J; Park YS; Kim HD; Ryu MH; Park Y; Moon M; Lee H; Kang YK
    Gastric Cancer; 2022 Jul; 25(4):794-803. PubMed ID: 35524883
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study.
    Haffner I; Schierle K; Raimúndez E; Geier B; Maier D; Hasenauer J; Luber B; Walch A; Kolbe K; Riera Knorrenschild J; Kretzschmar A; Rau B; Fischer von Weikersthal L; Ahlborn M; Siegler G; Fuxius S; Decker T; Wittekind C; Lordick F
    J Clin Oncol; 2021 May; 39(13):1468-1478. PubMed ID: 33764808
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
    Nishimura R; Toh U; Tanaka M; Saimura M; Okumura Y; Saito T; Tanaka T; Teraoka M; Shimada K; Katayama K; Koga T; Kurashita K; Hasegawa S; Todoroki H; Kai Y; Ohi Y; Toyoshima S; Arima N; Mitsuyama S; Tamura K
    Oncology; 2017; 93(1):51-61. PubMed ID: 28478451
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine.
    Hopkins AM; Rowland A; Logan JM; Sorich MJ
    Breast; 2019 Aug; 46():90-94. PubMed ID: 31170589
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.
    An E; Ock CY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Liao WL; Cecchi F; Blackler A; Thyparambil S; Kim WH; Burrows J; Hembrough T; Catenacci DVT; Oh DY; Bang YJ
    Ann Oncol; 2017 Jan; 28(1):110-115. PubMed ID: 27687309
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer.
    Satoh T; Kang YK; Chao Y; Ryu MH; Kato K; Cheol Chung H; Chen JS; Muro K; Ki Kang W; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Tanimoto M; Chen LT; Boku N
    Gastric Cancer; 2020 Jan; 23(1):143-153. PubMed ID: 31087200
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination of trastuzumab and taxane-containing intensified chemotherapy in first-line treatment of HER2-positive advanced gastric cancer.
    Gürbüz M; Akkuş E; Sakin A; Urvay S; Demiray AG; Şahin S; Şakalar T; Erol C; Şendur MAN; Şahin AB; Çubukçu E; Güven DC; Kılıçkap S; Ergün Y; Uncu D; Turhal NS; Üskent N; Yeşil Çınkır H; Demir A; Acar R; Karadurmuş N; Türker S; Altınbaş M; Karaoğlan M; Çay Şenler F
    Tumori; 2021 Oct; 107(5):416-423. PubMed ID: 33167790
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients.
    Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Segura-Pérez AM; Chamorro-Santos C; Vergara-Alcaide E; Castillo-Portellano L; Calleja-Hernández MÁ
    Pharmacol Res; 2016 Jun; 108():111-118. PubMed ID: 27137881
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term survival in trastuzumab-treated patients with HER2-positive metastatic breast cancer: real-world outcomes and treatment patterns in a whole-of-population Australian cohort (2001-2016).
    Daniels B; Kiely BE; Lord SJ; Houssami N; Lu CY; Ward RL; Pearson SA
    Breast Cancer Res Treat; 2018 Aug; 171(1):151-159. PubMed ID: 29736743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer.
    Kim SB; Wildiers H; Krop IE; Smitt M; Yu R; Lysbet de Haas S; Gonzalez-Martin A
    Int J Cancer; 2016 Nov; 139(10):2336-42. PubMed ID: 27428671
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
    Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
    Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
    Li Y; Peng Z; Zhang X; Gong J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer.
    Kijima T; Arigami T; Uenosono Y; Hiraki T; Yanagita S; Matsushita D; Okubo K; Shimonosono M; Ishigami S; Maemura K; Tanimoto A; Natsugoe S
    Anticancer Res; 2020 Jan; 40(1):75-80. PubMed ID: 31892554
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
    Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
    Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.